Risk Evaluation and Mitigation Strategy (REMS)

Shared System for Alosetron

Selective 5-HT₃ antagonist

I. GOAL(S):

The goals and objectives of the Alosetron REMS Program are to mitigate the risks of ischemic colitis (IC) and serious complications of constipation (CoC) associated with alosetron hydrochloride (hereinafter, referred to as alosetron) by:

- Informing prescribers of alosetron about:
  - the serious risks of IC and serious CoC associated with alosetron
  - the importance of understanding that alosetron should only be used in severely affected diarrhea-predominant irritable bowel syndrome patients for whom the benefits exceed the risks.
  - the importance of counseling patients about the risks of IC and serious CoC

- Informing patients about the risks of IC and CoC and actions to take should they experience early warning signs and symptoms of these risks.

II. REMS ELEMENTS:

A. Elements to Assure Safe Use
1. **Training will be provided to healthcare providers who prescribe alosetron.**

   a. The Alosetron Sponsors will ensure that training provided to healthcare providers who prescribe alosetron includes information on the serious risks of IC and CoC associated with alosetron, the importance of understanding that alosetron should only be used in severely affected diarrhea-predominant irritable bowel syndrome patients for whom the benefits exceed the risks, and the importance of counseling patients about the risks of IC and serious CoC, using the Alosetron Prescribing Information and the following materials in the REMS Training Kit:

      i. REMS letter to Healthcare Providers
      ii. Alosetron REMS Program Prescriber Education Slide Deck
      iii. Alosetron REMS Program Safety Information Fact Sheet for Prescribers
      iv. Alosetron REMS Program Patient Education Sheet
      v. Prescriber Completion of Alosetron REMS Program Training Form

   b. In order to facilitate training, the Alosetron Sponsors will:

      i. Monitor distribution and prescription data monthly.
      ii. Contact all prescribers identified as not having completed training and provide training within 30 days of identification by mailing or emailing the REMS Training Kit. Contact and provide training to all prescribers who do not report completion of training after the first contact up to two additional times, or until the prescriber reports completion, within 180 days of being first identified.
      iii. Ensure that prescribers can notify the Alosetron Sponsors when they have completed training via the Alosetron REMS Program website or by faxing a Prescriber Completion of Training Form.
      iv. Provide acknowledgement of completion of training electronically to prescribers upon receiving notification that training was completed.
      v. Make REMS Training Materials available at professional society meetings and at medical educational venues where the Alosetron Sponsors have a presence.
      vi. Maintain an Alosetron REMS Program website [www.AlosetronREMS.com] and contact center (1-844-267-8675) to support prescribers.
      vii. Maintain a validated, secure database of healthcare providers who have notified the Alosetron Sponsors of completion of training, which will be defined as all training materials were reviewed independently by the healthcare provider.
      viii. Ensure that the REMS materials listed below are available on the Alosetron REMS Program website or by calling the REMS contact center.
The following materials are part of the REMS and are appended:

- **REMS Training Kit**
  - REMS letter for Healthcare Providers
  - Alosetron REMS Program Prescriber Education Slide Deck
  - Alosetron REMS Program Safety Information Fact Sheet for Prescribers
  - Alosetron REMS Program Patient Education Sheet
  - Prescriber Completion of Alosetron REMS Program Training Form

- **Other appended REMS materials:**
  - Alosetron REMS Program website Prescriber Section screenshots
  - Alosetron REMS Program website Patients Section screenshots
To: Prescriber Name  
From: Alosetron REMS Program  
Phone: 1-844-267-8675 Fax: 1-800-535-6805  
Date: Current Date

Dear Prescriber Name,

The Alosetron REMS Program is an FDA mandated Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of alosetron outweigh the risks. Our records indicate that you have prescribed alosetron without having completed training in the Alosetron REMS Program. The Alosetron REMS Program states that you should complete training prior to prescribing alosetron.

To support your training in the Alosetron REMS Program, the following Training Kit materials are enclosed:

- Alosetron REMS Program Prescriber Education Slide Deck
- Alosetron REMS Program Safety Information Fact Sheet for Prescribers
- Alosetron REMS Program Patient Education Sheet
- Prescriber Completion of Alosetron REMS Program Training Form

The Training Kit is also available online at www.AlosetronREMS.com or you can request the Training Kit by calling the Alosetron REMS Program at 1-844-267-8675.

To become trained in the Alosetron REMS Program, review the training materials listed above, complete the Prescriber Completion of Alosetron REMS Program Training Form, and fax it to the program at 1-800-535-6805.

Alternatively, you can complete training on the Alosetron REMS Program website at www.AlosetronREMS.com.

**REMS Safety Information for Alosetron Tablets**

A non-promotional factsheet, reviewed by the FDA, with more detailed safety information about the risks of alosetron is enclosed.

**Indication:**
Alosetron is a selective serotonin 5-HT3 antagonist indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy.

Severe IBS includes diarrhea and 1 or more of the following:
• frequent and severe abdominal pain/discomfort
• frequent bowel urgency or fecal incontinence
• disability or restriction of daily activities due to IBS

Please visit www.AlosetronREMS.com for more information.

This letter does not contain the complete safety profile for alosetron. Please see the Prescribing Information and Medication Guide, enclosed.

**Reporting Adverse Events**
You are encouraged to report all suspected adverse events associated with alosetron to the FDA at www.fda.gov/medwatch, or 1-800-FDA-1088 or to the Alosetron REMS Program at 1-844-267-8675.

Sincerely,

The Alosetron REMS Program
THE ALOSETRON REMS PROGRAM

Prescriber Education Slide Deck

Understanding the Benefits and Risks of Alosetron
<table>
<thead>
<tr>
<th>Section 1</th>
<th>Purpose</th>
<th>Slide 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 2</td>
<td>Indication and Usage</td>
<td>Slide 7</td>
</tr>
<tr>
<td>Section 3</td>
<td>Important Safety Information</td>
<td>Slide 10</td>
</tr>
<tr>
<td>Section 4</td>
<td>How to Prescribe Alosetron Tablets</td>
<td>Slide 26</td>
</tr>
<tr>
<td>Section 5</td>
<td>Alosetron REMS Program</td>
<td>Slide 30</td>
</tr>
</tbody>
</table>
Section 1:

Purpose
Purpose of the Prescriber Education Slide Deck for Alosetron

• By reviewing the information provided in this presentation, prescribers who prescribe alosetron hydrochloride (alosetron) will better understand the:

- Risks and benefits of alosetron;

- Etiology of irritable bowel syndrome;

- The Alosetron REMS Program
Risk Evaluation and Mitigation Strategy (REMS)

• A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the FDA to manage known or potential serious risks associated with a drug product. FDA has determined that a REMS is necessary to ensure that the benefits of alosetron tablets outweigh serious gastrointestinal adverse reactions in patients.
Goals and Objectives

The Alosetron REMS Program was implemented to help reduce the risks of serious gastro-intestinal (GI) adverse events.

The goals and objectives of the Alosetron REMS Program are to mitigate the risks of ischemic colitis (IC) and serious complications of constipation (CoC) associated with alosetron hydrochloride (hereinafter, referred to as alosetron) by:

• Informing prescribers of alosetron about:
  – the serious risks of IC and serious CoC associated with alosetron
  – the importance of understanding that alosetron should only be used in severely affected diarrhea-predominant irritable bowel syndrome patients for whom the benefits exceed the risks.
  – the importance of counseling patients about the risks of IC and serious CoC

• Informing patients about the risks of IC and CoC and actions to take should they experience early warning signs and symptoms of these risks.
Section 2:

Indication and Usage
Indication and Usage

Alosetron is indicated ONLY for women with severe diarrhea-predominant IBS who have:

• chronic IBS symptoms (generally lasting 6 months or longer),

• had anatomic or biochemical abnormalities of the GI tract excluded, and

• not responded adequately to conventional therapy.
• Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following:
  - frequent and severe abdominal pain/discomfort,
  - frequent bowel urgency or fecal incontinence,
  - disability or restriction of daily activities due to IBS.

• Because of infrequent but serious GI adverse reactions associated with alosetron, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable.

• Clinical studies have not been performed to adequately confirm the benefits of alosetron in men.
Section 3:
Important Safety Information
BOXED WARNING

WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS

Infrequent but serious gastrointestinal adverse reactions have been reported with the use of alosetron. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, and death.
Boxed Warning (cont’d)

• Alosetron is indicated only for women with severe diarrhea-predominant IBS who have not responded adequately to conventional therapy.

• Alosetron should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis. Patients should immediately report constipation or symptoms of ischemic colitis to their prescriber. Alosetron should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their prescriber if the constipation does not resolve after alosetron is discontinued. Patients with resolved constipation should resume alosetron only on the advice of their treating prescriber.
Warnings and Precautions

Serious Complications of Constipation

• Some patients have experienced serious complications of constipation without warning. Examples include:

  - obstruction, ileus, impaction, toxic megacolon, and secondary bowel ischemia have been reported with use of alosetron during clinical trials.

  - in addition, rare cases of intestinal perforation and death have been reported from postmarketing clinical practice.

  - in some cases, complications of constipation required intestinal surgery, including colectomy.

The Alosetron REMS Program - Please see complete Prescribing Information for Alosetron Tablets for full details.
Warnings and Precautions (cont’d)

Serious Complications of Constipation (cont’d)

• The incidence of serious complications of constipation was \( \sim 0.1\% \), or 1 per 1,000 patients, in women receiving either alosetron or placebo.

• Patients who are elderly, debilitated, or taking additional medications that decrease GI motility may be at greater risk for complications of constipation.

• Alosetron should be discontinued immediately in patients who develop constipation.
Warnings and Precautions (cont’d)

Ischemic Colitis

- Some patients have experienced symptoms of ischemic colitis without warning.

- Ischemic colitis has been reported in patients receiving alosetron in clinical trials as well as during marketed use of the drug.

- In IBS clinical trials:
  - cumulative incidence of ischemic colitis in women receiving alosetron was:
    - 0.2%, or 2 per 1,000 patients (95% CI 1 to 3), over 3 months
    - 0.3%, or 3 per 1,000 patients (95% CI 1 to 4), over 6 months
  - patient experience in controlled clinical trials is insufficient to estimate the incidence of ischemic colitis in patients taking alosetron for longer than 6 months
Warnings and Precautions (cont’d)

Ischemic Colitis (cont’d)

- Alosetron should be discontinued immediately in patients with signs of ischemic colitis, e.g., rectal bleeding, bloody diarrhea, or new or worsening abdominal pain.

- Because ischemic colitis can be life threatening, patients with signs or symptoms of ischemic colitis should be evaluated promptly and have appropriate diagnostic testing performed.

- Treatment with alosetron should not be resumed in patients who develop ischemic colitis.
Contraindications

• Alosetron should not be initiated in patients with constipation.

• Alosetron is contraindicated in patients with a history of:
  – chronic or severe constipation or sequelae from constipation;
  – intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions;
  – ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state;
  – Crohn’s disease or ulcerative colitis;
  – diverticulitis;
  – severe hepatic impairment.

The Alosetron REMS Program - Please see complete Prescribing Information for Alosetron Tablets for full details.
Contraindications (cont’d)

• Concomitant administration of alosetron with fluvoxamine is contraindicated.
Drug Interactions

In vivo data suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron.

• Concomitant administration of alosetron and fluvoxamine is contraindicated.

• Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
Drug Interactions (cont’d)

• Caution should be used when alosetron and ketoconazole are administered concomitantly.

• Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.

• The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.
Use in Specific populations

- Pregnancy Category B.

- It is not known whether alosetron is excreted in human milk; caution should be exercised when alosetron is administered to a nursing woman.

- Safety and effectiveness in pediatric patients have not been established.

- Postmarketing experience suggests that elderly patients may be at greater risk for complications of constipation; therefore, appropriate caution and follow-up should be exercised if alosetron is prescribed for these patients.

The Alosetron REMS Program - Please see complete Prescribing Information for Alosetron Tablets for full details.
Use in Specific populations (cont’d)

• Increased exposure to alosetron and/or its metabolites is likely to occur in patients with hepatic impairment. Alosetron should not be used in patients with severe hepatic impairment and should be used with caution in patients with mild or moderate hepatic impairment.
Adverse Reactions Reported in ≥ 1% of IBS Patients\(^a\)

<table>
<thead>
<tr>
<th>Gastrointestinal Adverse Reactions</th>
<th>Alosetron 1 mg BID (n=8,328(^b))</th>
<th>Placebo (n=2,363)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation(^c)</td>
<td>29%</td>
<td>6%</td>
</tr>
<tr>
<td>Abdominal discomfort and pain</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>Nausea</td>
<td>6%</td>
<td>5%</td>
</tr>
<tr>
<td>GI discomfort and pain</td>
<td>5%</td>
<td>3%</td>
</tr>
<tr>
<td>Abdominal distention</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Regurgitation and reflux</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Hemorrhoids</td>
<td>2%</td>
<td>1%</td>
</tr>
</tbody>
</table>

\(^a\) Reported in ≥1% of alosetron patients and occurring more frequently on alosetron 1 mg twice-a-day than on placebo.

\(^b\) Data reported from 22 repeat-dose studies in patients with IBS treated for 8 to 24 weeks.

\(^c\) \(P<0.0001\) vs placebo.
Adverse Reactions

Constipation is a frequent and dose-related side effect of treatment with alosetron.

• In clinical studies constipation was reported in ~29% of patients with IBS treated with alosetron 1 mg twice daily (n=9,316).
  – The effect was statistically significant compared with placebo ($P<0.0001$);
  – 11% of patients treated with alosetron 1 mg twice daily withdrew from the studies due to constipation.

• Although the number of IBS patients treated with alosetron 0.5 mg twice daily is relatively small (n=243), 11% of patients reported constipation and 4% of patients withdrew from clinical studies due to constipation.
Overdosage

- No specific antidote available for overdose of alosetron.
- Patients should be managed with appropriate supportive therapy.
Section 4:
How to Prescribe Alosetron Tablets
Dosage and Administration

• Usual Dose in Adults
  – To lower the risk of constipation, alosetron should be started at 0.5 mg twice-a-day.
  – Patients well controlled on 0.5 mg twice-a-day may be maintained on this regimen.
  – If, after 4 weeks, the 0.5 mg twice-a-day dosage is tolerated but does not adequately control IBS symptoms, increase dose to 1 mg twice-a-day, the dose used in controlled clinical trials.
Dosage and Administration (cont’d)

• Usual Dose in Adults
  – Alosetron should be started at a dosage of 0.5 mg twice-a-day. Patients controlled on this dose may be maintained on this regimen.
  – If after 4 weeks, the 0.5 mg twice-a-day dosage is well tolerated but does not adequately control the IBS symptoms, then the dosage can be increased up to 1 mg twice-a-day.
  – Alosetron should be discontinued in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice-a-day.
  – Alosetron should be discontinued immediately in patients who develop constipation or signs of ischemic colitis.
  – Alosetron should not be restarted in patients who develop ischemic colitis.
Dosage and Administration (cont’d)

• Clinical trial and postmarketing experience suggest that debilitated patients or patients taking additional medications that decrease GI motility may be at greater risk of serious complications of constipation.

• Therefore, appropriate caution and follow-up should be exercised if alosetron is prescribed for these patients.

• Alosetron can be taken with or without food.
Section 5:

Alosetron REMS Program

The Alosetron REMS Program - Please see complete Prescribing Information for Alosetron Tablets for full details.
Training in the Alosetron REMS Program

• Prescribers should read the Prescribing Information (PI) and other training materials to understand the benefits and risks of treatment with alosetron for severe diarrhea-predominant IBS.

• Prescribers can communicate the completion of training by filling out the Prescriber Completion of Alosetron REMS Program Training Form at www.AlosetronREMS.com or return it by fax.

• The form must be completed and returned to the Alosetron REMS Program before a prescriber can be considered trained in the program.
Training in the Alosetron REMS Program (cont’d)

- Alosetron REMS Training Kit includes the following:
  - REMS letter for Healthcare Providers
  - Alosetron REMS Program Prescriber Education Slide Deck
  - Alosetron REMS Program Safety Information Fact Sheet for Prescribers
  - Alosetron REMS Program Patient Education Sheet
  - Prescriber Completion of Alosetron REMS Program Training Form
Patient Education

• Once you have selected an appropriate patient for therapy:
  – provide the patient with the Alosetron Patient Education Sheet
  – review it together with the patient and explain the risks of therapy
  – answer any questions the patient may have.

• Instruct the patient to read the Medication Guide supplied with the product
Patient Responsibilities

Patients should be instructed to:

• read the Alosetron Patient Education Sheet before starting alosetron.

• read the Medication Guide before starting alosetron and each time they refill their prescription.

• not take alosetron if they are constipated.

• immediately discontinue alosetron and contact their prescriber if they become constipated or have symptoms of ischemic colitis such as new or worsening abdominal pain, bloody diarrhea, or blood in the stool.

• immediately contact their prescriber again if their constipation does not resolve after discontinuation of alosetron.
Patient Responsibilities (cont’d)

Patients should be instructed to:

• resume alosetron only if their constipation has resolved and after discussion with and the agreement of their treating prescriber.

• stop taking alosetron and contact their prescriber if alosetron does not adequately control IBS symptoms after 4 weeks of taking 1 mg twice-a-day.
• You have now reached the end of this Education Slide Deck.

• If you have questions about the Alosetron REMS Program, please call 1-844-267-8675 or visit www.AlosetronREMS.com.
RISK OF SERIOUS GASTROINTESTINAL ADVERSE REACTIONS

- Infrequent but serious gastrointestinal adverse reactions have been reported with the use of alosetron hydrochloride tablets (alosetron). These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization and, rarely, blood transfusion, surgery, and death.

- INDICATED ONLY for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy

- DISCONTINUE alosetron immediately in patients who develop constipation or symptoms of ischemic colitis. Do not resume alosetron in patients who develop ischemic colitis

- Contraindicated in patients with:
  - Constipation
  - History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn’s disease or ulcerative colitis; diverticulitis; severe hepatic impairment
  - Concomitant use of fluvoxamine (LUVOX®)

Risk of Serious Gastrointestinal Adverse Reactions

- Counsel patients to discontinue alosetron immediately and contact you right away if they develop constipation or symptoms of ischemic colitis
- Evaluate patients with signs of ischemic colitis (e.g., rectal bleeding, bloody diarrhea, new or worsening abdominal pain)
- Discontinue alosetron immediately if signs of ischemic colitis occur, such as rectal bleeding, bloody diarrhea, or new or worsening abdominal pain.

Appropriate Patient Selection

Prescribers should select the appropriate patients to receive alosetron in accordance with the approved indication. Alosetron is contraindicated in patients with constipation, history of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn’s disease or ulcerative colitis; diverticulitis; severe hepatic impairment; and patients on fluvoxamine (LUVOX®).

*What is the Alosetron REMS Program?*

A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the FDA to manage known or potential serious risks associated with a drug product. FDA has determined that a REMS is necessary to ensure that the benefits of alosetron tablets outweigh serious gastrointestinal adverse reactions in patients. This factsheet is required by the FDA as part of the Alosetron REMS Program. Please visit www.AlosetronREMS.com for further information.
**Indication**

Alosetron is a selective serotonin 5-HT3 antagonist indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy.

Severe IBS includes diarrhea and 1 or more of the following:

- frequent and severe abdominal pain/discomfort
- frequent bowel urgency or fecal incontinence
- disability or restriction of daily activities due to IBS

**Reporting Adverse Events**

You are encouraged to report all suspected adverse events associated with alosetron to the FDA at [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or 1-800-FDA-1088 or to the Alosetron REMS Program at 1-844-267-8675.

*This factsheet does not contain the complete safety profile for alosetron. Please refer to the Alosetron Prescribing Information, including Boxed Warning, for further information.*
FDA Required Alosetron Safety Information

What is alosetron?

• Alosetron is a prescription medicine only for women with severe irritable bowel syndrome (IBS) whose main problem is diarrhea and who did not get the relief needed from other treatments. Alosetron has not been shown to help men with irritable bowel syndrome (IBS) or patients under age 18.

What is the most serious risk information about alosetron treatment?

• About 1 out of every 1,000 women who take alosetron may get serious complications of constipation. About 3 out of every 1,000 women who take alosetron over a 6-month period may get a serious problem where blood flow to parts of the large bowel is reduced (ischemic colitis).
• The serious condition of ischemic colitis, and other serious complications of constipation, can happen suddenly. These complications may lead to a hospital stay, and in rare cases, blood transfusions, surgery, and death.
• Certain patients may be more likely to develop a serious bowel condition while taking alosetron. These include older patients, those who have other health problems and those who take other medicines that may cause constipation.

What should I tell my doctor before I start taking alosetron?

• Tell your doctor about any illnesses you have, or other medicines you are taking or planning to take.

How do I take alosetron?

• Take alosetron exactly as your doctor prescribes it.

When should I stop taking alosetron and call my doctor?

• Stop taking alosetron and call your doctor right away if you get constipated, if you have new or worse pain in your stomach area (abdomen), or if you see blood in your bowel movements.
• Call your doctor again if the constipation you called about before has not gotten better.
• Do not start taking alosetron again unless your doctor tells you to do so, if you stopped taking it because you got constipated.
• Talk with your doctor 4 weeks after starting alosetron to recheck your IBS symptoms.
• Stop taking alosetron and call your doctor if your IBS symptoms have not improved after 4 weeks of taking 1 mg of alosetron 2 times a day.
• If you see other doctors about your IBS or possible side effects from alosetron, tell the doctor who prescribed alosetron.

This education sheet only discusses the most serious risk information of alosetron. For more safety information about alosetron please see the alosetron medication guides available at www.AlosetronREMS.com

Please visit www.AlosetronREMS.com for further information.
Prescriber Completion of Alosetron REMS Program Training Form

Thank you for completing the Alosetron REMS Program training. As a confirmation that you independently reviewed the provided training materials, please provide your details in the form below. Upon receipt you will be sent an acknowledgment notice.

*Indicates Required Field

Name of Prescriber (print)*

_________________________________________________
(First)                                          (Last)

_________________________________________________
Signature*                                         Date*

NPI Number*  
Specialty*  
☐ Gastroenterology  ☐ General Surgery  ☐ Internal Medicine  
☐ Colon & Rectal Surgery  ☐ Nurse Practitioner  ☐ Nuclear Medicine  
☐ Family Medicine  ☐ Cardiovascular Diseases  ☐ Physician Assistant  
☐ Obstetrics/Gynecology  ☐ Other (Please specify) ______________________________

Office Name  
Office Address*  
Office City*  
__________________________________________ State* _______ Zip Code* __________

Office Phone Number*  
Office Fax Number*  
Email*  
__________________________________________

Confirmation Correspondence Preference (please select one): ☐ Fax    ☐ Email

If you have any questions regarding the Alosetron REMS Program, please call 1-844-267-8675.

To complete training, visit www.AlosetronREMS.com or complete this form in its entirety and fax it to the Alosetron REMS Program to the following:

Fax Number: 1-800-535-6805

Version 2.0 – June 7, 2021
What is the Alosetron REMS Program?

1. A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the Food and Drug Administration (FDA) to manage known or potential serious risks associated with a drug product. The FDA has determined that a REMS is necessary for alosetron to ensure the benefits of the drug outweigh the risk of serious gastrointestinal (GI) adverse reactions.

2. The Alosetron REMS Program was implemented to help reduce the risks of a serious GI adverse event.

Only patients who are counseled on the safe use of alosetron by their prescriber should be prescribed alosetron.

Only prescribers who train in the Alosetron REMS Program, based on their understanding of the benefits and risks, should prescribe alosetron.

If you are an alosetron prescriber, you can begin the training by clicking the button below.

To report any SUSPECTED ADVERSE REACTIONS, contact the Alosetron REMS Contact Center at 1-844-267-8675 or FDA at 800-FDA-1088 or http://www.fda.gov/medwatch.
What is a patient's role in the Alosetron REMS?

**Talk With your Doctor**

- Only patients who are counseled on the safe use of alosetron by their prescriber should be prescribed alosetron. Patients will:
  - be counseled on the Alosetron REMS Program by trained prescribers.
  - have the opportunity to discuss any questions or concerns they have with their prescriber.
- The prescriber will provide and review the Alosetron REMS Program Patient Education Sheet with the patient at the beginning of treatment. Please use the links in the Patient Materials Section to review the Alosetron REMS Program Patient Education Sheet and Medication Guides.
Only prescribers who train in the Alosetron REMS Program, based on their understanding of the benefits and risks, should prescribe alosetron.

**What is the prescriber's role in the Alosetron REMS Program?**

Only prescribers who train in the Alosetron REMS Program, based on their understanding of the benefits and risks, should prescribe alosetron. Alosetron REMS Program facilitates patient's safety. The program requires patients and prescribers to understand the appropriate use of alosetron and its potential risks, as well as potential adverse events and how to handle them.

**Complete the Prescriber Training**

Successfully complete the Prescriber Training Online or Print and fax the completed Prescriber Completion of Alosetron REMS Program Training to the Alosetron REMS Program at 1-800-535-6805.

1. [Online](#) or [Print](#)
Prescribers should comply with the following requirements of the Alosetron REMS Program:

1. Review the Alosetron REMS Program Prescriber Education Slide Deck
2. Fill out the Prescriber Completion of Alosetron REMS Program Training Form
3. Sign and Submit the form to complete your training

1. Review the Alosetron REMS Prescriber Education Slide Deck:

THE ALOSETRON
REMS PROGRAM

Prescriber Education Slide Deck

Understanding the Benefits and Risks of Alosetron
2. Fill out the Prescriber Completion of Alosetron REMS Program Training Form

Individual NPI Number*

NPI

Office Name

Office Name

First Name*

First Name

Last Name*

Last Name

Specialty*

Please select a specialty

Office Address Line 1*

Office Address Line 1

Office Address Line 2

Office Address Line 2

Office City*

Office City

State* Select your state

Zip Code*

Zip Code

Office Phone* Ext. Office Fax*

Office Phone Ext. Office Fax

Email* Email

Preferred Method of Contact*

Email Fax

3. Sign and Submit the form to complete your training*

Sign Type Signature

Please use your mouse or stylus to sign below

I authorize the above signature to be the legally binding equivalent of my handwritten signature. Sign and Submit

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Contact the Alosetron REMS Contact Center

Phone
1-844-267-8675

Fax
1-800-535-6805

--- Or ---

Contact a participating company about a specific product

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Company</th>
<th>Phone</th>
<th>NDC Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alosetron Hydrochloride</td>
<td>Amneal Pharmaceuticals LLC</td>
<td>(908) 947-3120</td>
<td>65162-248-03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>65162-248-50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>65162-249-03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>65162-249-50</td>
</tr>
<tr>
<td>Alosetron Hydrochloride</td>
<td>Par Pharmaceutical, Inc.</td>
<td>(845) 573-5500</td>
<td>49884-819-11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>49884-820-11</td>
</tr>
<tr>
<td>Alosetron Hydrochloride</td>
<td>Hikma Pharmaceuticals USA Inc.</td>
<td>(856) 424-3700</td>
<td>0054-0295-13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0054-0296-13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0054-0296-25</td>
</tr>
<tr>
<td>Alosetron Hydrochloride</td>
<td>Rising Pharmaceuticals, Inc.</td>
<td>(201) 961-9000</td>
<td>64980-453-03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>64980-453-50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>64980-454-03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>64980-454-50</td>
</tr>
<tr>
<td>Alosetron</td>
<td>Lifestar Pharma LLC</td>
<td>(201) 818-2040</td>
<td>70756-701-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>70756-702-30</td>
</tr>
</tbody>
</table>
Alosetron REMS Terms of Use

This Web site was developed as a service provided by the suppliers of alosetron-containing products participating in the Alosetron REMS. This Web site provides selected information available about the suppliers of alosetron-containing products in the U.S. Like any printed material, it may become out of date over time. This information is not intended to be a substitute for the advice of a healthcare professional, or a recommendation for any particular treatment plan. It is important that consumers rely on the advice of a healthcare professional for detailed information about medical conditions and treatment.

The suppliers of alosetron-containing products have made and will continue to make efforts to include accurate and up-to-date information on this Web site. However, the suppliers of alosetron-containing products make no warranties or representations, express or implied, as to the accuracy or completeness of the information contained or referenced herein. This information is provided "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

All images and information contained in this Web site are copyrighted and otherwise proprietary. Unless otherwise indicated, all logos, designs, and marks on this Web site are trademarks or service marks owned or used under license by the suppliers of alosetron-containing products, or their affiliates. All product names printed in capitals or otherwise appropriately marked in this Web site are trademarks of the suppliers of alosetron-containing products. Unless otherwise expressly noted, nothing on this Web site may be copied or used except as provided in these Terms of Use or with the prior written consent of the suppliers of alosetron-containing products.

The suppliers of alosetron-containing products grant you permission to print individual pages from this Web site, unless otherwise expressly noted, for your own personal, non-commercial use in learning about services or products offered by the suppliers of alosetron-containing products or for your non-commercial use in connection with healthcare or education. No other permission is granted to you to print, copy, reproduce, distribute, license, transfer, sell, transmit, upload, download, store, display in public, alter, modify or create derivative works of these materials. This grant of permission is not a transfer of title.

All users agree that all access and use of this Web site and on any site linked to this Web site and the content thereof is at their own risk. Neither the suppliers of alosetron-containing products, nor any other party involved in creating, producing or delivering this Web site or any site linked to this Web site, shall be liable in any manner whatsoever for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this Web site or any site linked to this Web site. Any links to or from this Web site are strictly prohibited without the prior written consent of the suppliers of alosetron-containing products.